EU/3/20/2253

Table of contents

About

On 28 February 2020, orphan designation EU/3/20/2253 was granted by the European Commission to Consorcio Centro de Investigación Biomédica en Red, M.P, Spain, for autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80 for the treatment of epidermolysis bullosa.

Key facts

Active substance
Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
28/02/2020
Outcome
Positive
EU designation number
EU/3/20/2253

Sponsor's contact details

Consorcio Centro de Investigación Biomédica en Red, M.P.
Pab 11
Avenida Monforte De Lemos 3-5
28029 Madrid
Spain
Tel: + 34 911 718 114
E-mail: gestores@ciberer.es

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating